在不可切除的III期ALK阳性NSCLC化疗后，联合ALK酪氨酸激酶抑制剂对比Durvalumab或观察

文章预览

国庆节快乐 SCI 1 October 2024 Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC (Journal of Thoracic Oncology；IF：21) Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY, Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer, Journal of Thoracic Oncology (2024), doi: https://doi.org/10.1016/j.jtho.2024.09.1379.  Correspondence:  Amin H. Nassar, MD Yale University School of Medicine, New Haven, CT ………………………………